Business Context and Reporting Period
This Form 8-K is a current report filed by Sutro Biopharma, Inc. (STRO) on December 17, 2025. The filing addresses a specific corporate event regarding the company's listing status on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On December 17, 2025, the company received confirmation from Nasdaq that it has regained compliance with Listing Rule 5450(a)(1). This follows a notice received on June 20, 2025, indicating non-compliance due to the closing bid price falling below $1.00 per share for 30 consecutive business days.
Outlook and Management Commentary
Management confirms that as of December 16, 2025, the closing bid price of the common stock had been at least $1.00 per share for 10 consecutive business days. Consequently, the company satisfies all other applicable criteria for continued listing, and the listing matter is now closed. No forward-looking guidance or risk factors beyond the resolved listing issue are discussed in this document.
Investor Verification Checklist
- Verify the current trading price of STRO to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the company's continued compliance with other Nasdaq listing requirements beyond the minimum bid price.
- Review recent financial filings (10-K or 10-Q) for updated data on cash runway and operational progress, as this 8-K contains no financial metrics.